Metraipolis › archive › dc_64fd925f7768

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity — Europe PMC PMID:42266018

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42266018
DOI
10.1002/ijc.70580
License (as archived)
solo-consultazione
Archived
2026-10-31T16:03:40.570Z
SHA-256 of the archived text
36fbf3058a61b69f7913024ee9e0154536c23c6c953ade27c932454734d554c3
Stable URL of this page
https://metraipolis.com/documento/dc_64fd925f7768

How to cite

DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity — Europe PMC PMID:42266018 — Europe PMC (en), https://europepmc.org/article/MED/42266018 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_64fd925f7768 (Metraipolis archive dc_64fd925f7768, sha256 36fbf3058a61b69f7913024ee9e0154536c23c6c953ade27c932454734d554c3)
BibTeX
@misc{dc64fd925f7768,
  title = {DPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity — Europe PMC PMID:42266018},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42266018},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_64fd925f7768; sha256 36fbf3058a61b69f7913024ee9e0154536c23c6c953ade27c932454734d554c3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42266018. Agents can read the archived copy with the MCP tool read_document.